NCT05204355View on ClinicalTrials.gov

MRI for Screening and Monitoring Scleroderma ILD

Active, not recruitingOBSERVATIONAL
Enrollment

25

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

March 31, 2025

Study Completion Date

October 31, 2025

Conditions
Scleroderma
Interventions
DIAGNOSTIC_TEST

MRI

Patients will be imaged using MRI

DRUG

Hyperpolarized Xe129

Hyperpolarized Xe129 will be used to image the lungs of a subset of participants.

DIAGNOSTIC_TEST

HRCT

High Resolution Computer Tomography

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

All Listed Sponsors
collaborator

Scleroderma Foundation

UNKNOWN

lead

University of Kansas Medical Center

OTHER